Voglinorm M Tablets contain Voglibose 0.2 mg/0.3 mg and Metformin Hydrochloride 500 mg. This fixed-dose combination combines an alpha-glucosidase inhibitor with a biguanide antihyperglycaemic agent to improve glycaemic control in patients with Type 2 Diabetes Mellitus.

Voglinorm M Tablets provide dual-action glycaemic control through complementary mechanisms of Voglibose and Metformin. Voglibose delays intestinal carbohydrate digestion and absorption, thereby reducing postprandial blood glucose excursions, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity. This combination effectively controls both fasting and postprandial blood glucose levels and is suitable for patients inadequately controlled with monotherapy.

Voglinorm M Tablets are indicated as second-line therapy for Type 2 Diabetes Mellitus in patients whose blood glucose levels remain inadequately controlled despite diet, exercise, and single-agent antidiabetic therapy.

Voglinorm M Tablets are indicated as second-line therapy for Type 2 Diabetes Mellitus in patients whose blood glucose levels remain inadequately controlled despite diet, exercise, and single-agent antidiabetic therapy.

The recommended dosage is one tablet twice daily, or as directed by the treating physician. The dosage should be individualized according to the patient's glycaemic response and clinical condition.

Voglinorm M Tablets are contraindicated in patients with known hypersensitivity to Voglibose, Metformin, or any component of the formulation. They are also contraindicated in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, and in patients with renal dysfunction. Treatment should be temporarily discontinued in patients undergoing radiological studies involving contrast media, as recommended by the treating physician.